Docetaxel 120mg Injection Exporter from India to USA – Ernest Oncology

Comprehensive Guide to Docelieva RTU 120mg Injection: Global Export & Distribution by Ernest Oncology

At Ernest Oncology (a division of Ernest Pharmaceutical Pvt. Ltd.), we are an internationally recognized exporter, bulk supplier, and distributor of critical oncology formulations. We specialize in the secure, compliant, and efficient supply of Docelieva RTU 120mg Injection (Docetaxel Injection) to healthcare providers, hospitals, and pharmaceutical distributors worldwide, with targeted delivery networks in the USA, UK, Australia, and South Africa.

This comprehensive guide covers the medical profile, mechanisms, uses, and an extensive list of SEO keywords designed to boost the online visibility of B2B pharmaceutical suppliers.

1. Product Information: Docelieva RTU 120mg Injection

Docelieva RTU 120mg Injection is a ready-to-use (RTU) formulation containing Docetaxel, a potent anti-cancer medication that belongs to the taxoid class. It is used to halt the rapid multiplication and spread of cancer cells in the body.

Key Product Details

• Composition: Docetaxel (120 mg / 6 mL vial).

• Therapeutic Class: Anti-neoplastic agent / Chemotherapeutic medication.

• Mechanism Class: Antimicrotubular inhibitor.

• Dosage Form: Concentrate for solution for intravenous (IV) infusion.

2. Mechanism of Action

Docelieva RTU 120mg targets the structural framework of cancer cells through the following steps:

• Microtubule Stabilization: Docetaxel binds to free tubulin and promotes the assembly of microtubules while simultaneously preventing their breakdown, locking the cell in the G2/M phase of the cell cycle.

• Mitotic Arrest: By preventing the microtubules from functioning correctly, normal cell division is halted.

• Apoptosis: The inability of the cell to divide triggers apoptosis (programmed cell death), selectively killing malignant cells and halting tumor growth. It also suppresses the BCL2 gene, further enhancing cancer cell vulnerability.

3. Therapeutic Indications and Uses

Docelieva RTU 120mg is indicated for the treatment of several solid tumors, often administered as part of a combination regimen or as a standalone agent:

• Breast Cancer: Used for both early-stage post-surgery treatment and locally advanced or metastatic breast cancer.

• Prostate Cancer: Administered alongside prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer.

• Non-Small Cell Lung Cancer (NSCLC): Administered alongside other platinum-based agents or as a single agent for advanced lung tumors.

• Gastric Adenocarcinoma: Used in combination with cisplatin and fluorouracil.

• Head and Neck Cancer (SCCHN): Used for induction treatment alongside other antineoplastic agents.

4. Administration and Storage

Administration

• Route: Administered exclusively via intravenous (IV) infusion under the supervision of an experienced oncologist or healthcare professional.

• Protocol: Given as a 1-hour intravenous infusion, generally repeated every three weeks.

• Pre-medication: Patients are typically pre-medicated with corticosteroids (such as oral dexamethasone) to reduce fluid retention (edema) and hypersensitivity reactions.

Storage and Handling

• Storage Temperature: Store at room temperature (between 15°C and 25°C). Do not freeze. Keep the vial in the outer carton to protect from light.

• Keep out of reach of children.

5. Potential Side Effects and Safety Warnings

• Common Side Effects: Low white blood cell counts (neutropenia), anemia, nausea, vomiting, fluid retention (peripheral edema), fatigue, muscle/joint pain, hair loss (alopecia), and peripheral neuropathy (tingling or numbness in hands and feet).

• Serious Risks: Myelosuppression, severe hypersensitivity reactions (swelling of the face, throat, and lips; difficulty breathing).

• Contraindications: Highly unsafe during pregnancy and lactation. Regular blood monitoring is required before and during treatments to monitor for hepatotoxicity and bone marrow suppression